NO823556L - 1-(3-(6-fluor-1,2-benzisoksazol-3-yl)propyl)-4-(substituert)-piperaziner og -piperidiner, fremgangsmaate til fremstilling av disse, farmasoeytiske blandinger inneholdende disse og deres bruk som legemidler - Google Patents

1-(3-(6-fluor-1,2-benzisoksazol-3-yl)propyl)-4-(substituert)-piperaziner og -piperidiner, fremgangsmaate til fremstilling av disse, farmasoeytiske blandinger inneholdende disse og deres bruk som legemidler

Info

Publication number: NO823556L
Authority: NO; Norway
Prior art keywords: formula; fluoro; compound; lower alkyl; propyl
Prior art date: 1982-04-09

Application number

NO823556A

Other languages

English (en)

Norwegian (no)

Inventor

Larry Davis

Joseph Thomas Klein

Original Assignee

Hoechst Roussel Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-04-09

Filing date

1982-10-26

Publication date

1983-10-10

1982-04-09 Priority claimed from US06/366,244 external-priority patent/US4390544A/en

1982-04-09 Priority claimed from US06/366,248 external-priority patent/US4536578A/en

1982-10-26 Application filed by Hoechst Roussel Pharma filed Critical Hoechst Roussel Pharma

1983-10-10 Publication of NO823556L publication Critical patent/NO823556L/no

Links

238000000034 method Methods 0.000 title claims abstract description 13
239000003814 drug Substances 0.000 title claims description 10
239000000203 mixture Substances 0.000 title description 24
229940079593 drug Drugs 0.000 title description 6
OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical class [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 52
125000000217 alkyl group Chemical group 0.000 claims description 20
150000003839 salts Chemical class 0.000 claims description 18
125000003545 alkoxy group Chemical group 0.000 claims description 13
239000001257 hydrogen Substances 0.000 claims description 12
229910052739 hydrogen Inorganic materials 0.000 claims description 12
229910052736 halogen Inorganic materials 0.000 claims description 11
150000002367 halogens Chemical class 0.000 claims description 11
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
239000002253 acid Substances 0.000 claims description 9
239000002904 solvent Substances 0.000 claims description 9
150000002431 hydrogen Chemical group 0.000 claims description 7
230000003287 optical effect Effects 0.000 claims description 7
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
238000006243 chemical reaction Methods 0.000 claims description 4
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
238000006073 displacement reaction Methods 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
125000004076 pyridyl group Chemical group 0.000 claims description 3
239000000126 substance Substances 0.000 claims description 3
229910000288 alkali metal carbonate Inorganic materials 0.000 claims description 2
150000008041 alkali metal carbonates Chemical group 0.000 claims description 2
229910001508 alkali metal halide Inorganic materials 0.000 claims description 2
150000008045 alkali metal halides Chemical group 0.000 claims description 2
KZKRRZFCAYOXQE-UHFFFAOYSA-N 1$l^{2}-azinane Chemical group C1CC[N]CC1 KZKRRZFCAYOXQE-UHFFFAOYSA-N 0.000 claims 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 1
239000004480 active ingredient Substances 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
239000000825 pharmaceutical preparation Substances 0.000 claims 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
238000002360 preparation method Methods 0.000 abstract description 9
-1 1-[3-(6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-4-(substituted)-piperazines Chemical class 0.000 abstract description 8
230000036772 blood pressure Effects 0.000 abstract description 5
208000028017 Psychotic disease Diseases 0.000 abstract description 3
230000036407 pain Effects 0.000 abstract description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 60
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 54
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 51
239000003921 oil Substances 0.000 description 35
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 22
239000000243 solution Substances 0.000 description 21
230000035939 shock Effects 0.000 description 20
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 18
238000012360 testing method Methods 0.000 description 18
XONBKLFCLPGIPC-UHFFFAOYSA-N 3-(3-chloropropyl)-6-fluoro-1,2-benzoxazole Chemical compound FC1=CC=C2C(CCCCl)=NOC2=C1 XONBKLFCLPGIPC-UHFFFAOYSA-N 0.000 description 16
238000004458 analytical method Methods 0.000 description 16
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 15
239000000047 product Substances 0.000 description 15
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 15
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
238000000354 decomposition reaction Methods 0.000 description 14
238000001953 recrystallisation Methods 0.000 description 14
230000004044 response Effects 0.000 description 13
241000282693 Cercopithecidae Species 0.000 description 12
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 11
239000000538 analytical sample Substances 0.000 description 11
229910000027 potassium carbonate Inorganic materials 0.000 description 11
235000011181 potassium carbonates Nutrition 0.000 description 11
239000013078 crystal Substances 0.000 description 10
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 10
229910000041 hydrogen chloride Inorganic materials 0.000 description 10
241001465754 Metazoa Species 0.000 description 9
239000012259 ether extract Substances 0.000 description 9
238000001914 filtration Methods 0.000 description 9
230000037396 body weight Effects 0.000 description 8
239000000706 filtrate Substances 0.000 description 8
230000000561 anti-psychotic effect Effects 0.000 description 7
229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
235000017557 sodium bicarbonate Nutrition 0.000 description 7
229960004046 apomorphine Drugs 0.000 description 6
230000009194 climbing Effects 0.000 description 6
230000000694 effects Effects 0.000 description 6
235000006408 oxalic acid Nutrition 0.000 description 6
241000124008 Mammalia Species 0.000 description 5
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 5
239000002244 precipitate Substances 0.000 description 5
241000699670 Mus sp. Species 0.000 description 4
239000002775 capsule Substances 0.000 description 4
239000000284 extract Substances 0.000 description 4
238000003756 stirring Methods 0.000 description 4
239000000725 suspension Substances 0.000 description 4
YDMASWQKRBOMKD-UHFFFAOYSA-N 3-(3-piperazin-1-ylpropyl)-1,2-benzoxazole Chemical class N=1OC2=CC=CC=C2C=1CCCN1CCNCC1 YDMASWQKRBOMKD-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
208000012661 Dyskinesia Diseases 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
241000282695 Saimiri Species 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
150000001735 carboxylic acids Chemical class 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000009833 condensation Methods 0.000 description 3
230000005494 condensation Effects 0.000 description 3
230000000142 dyskinetic effect Effects 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
BYNBAMHAURJNTR-UHFFFAOYSA-N 3-piperidin-4-yl-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC=CC=C2N1C1CCNCC1 BYNBAMHAURJNTR-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
239000000370 acceptor Substances 0.000 description 2
229940035676 analgesics Drugs 0.000 description 2
239000000730 antalgic agent Substances 0.000 description 2
239000000164 antipsychotic agent Substances 0.000 description 2
229940005529 antipsychotics Drugs 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
239000008298 dragée Substances 0.000 description 2
SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000006187 pill Substances 0.000 description 2
150000004885 piperazines Chemical class 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000008174 sterile solution Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000003826 tablet Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002627 tracheal intubation Methods 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
RXPHNGRBTQWKEQ-UHFFFAOYSA-N 1-(2-chlorophenyl)piperazine;hydrate;hydrochloride Chemical compound O.Cl.ClC1=CC=CC=C1N1CCNCC1 RXPHNGRBTQWKEQ-UHFFFAOYSA-N 0.000 description 1
NCENNBIPRYOJSP-UHFFFAOYSA-N 1-(2-methylphenyl)piperazine-1,4-diium;dichloride Chemical compound Cl.Cl.CC1=CC=CC=C1N1CCNCC1 NCENNBIPRYOJSP-UHFFFAOYSA-N 0.000 description 1
KKIMDKMETPPURN-UHFFFAOYSA-N 1-(3-(trifluoromethyl)phenyl)piperazine Chemical compound FC(F)(F)C1=CC=CC(N2CCNCC2)=C1 KKIMDKMETPPURN-UHFFFAOYSA-N 0.000 description 1
UKUNKQNESKRETR-UHFFFAOYSA-N 1-(3-methoxyphenyl)piperazine-1,4-diium;dichloride Chemical compound Cl.Cl.COC1=CC=CC(N2CCNCC2)=C1 UKUNKQNESKRETR-UHFFFAOYSA-N 0.000 description 1
AVJKDKWRVSSJPK-UHFFFAOYSA-N 1-(4-fluorophenyl)piperazine Chemical compound C1=CC(F)=CC=C1N1CCNCC1 AVJKDKWRVSSJPK-UHFFFAOYSA-N 0.000 description 1
MMXANKLJIHSIQH-UHFFFAOYSA-N 1-(4-methoxyphenyl)piperazine-1,4-diium;dichloride Chemical compound Cl.Cl.C1=CC(OC)=CC=C1N1CCNCC1 MMXANKLJIHSIQH-UHFFFAOYSA-N 0.000 description 1
UFKSGKWZRHCDND-UHFFFAOYSA-N 1-(4-methoxyphenyl)piperazine;oxalic acid Chemical compound OC(=O)C(O)=O.C1=CC(OC)=CC=C1N1CCNCC1 UFKSGKWZRHCDND-UHFFFAOYSA-N 0.000 description 1
PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
IQXXEPZFOOTTBA-UHFFFAOYSA-N 1-benzylpiperazine Chemical compound C=1C=CC=CC=1CN1CCNCC1 IQXXEPZFOOTTBA-UHFFFAOYSA-N 0.000 description 1
SBJSIKFDCGEKRZ-UHFFFAOYSA-N 1-butylpiperazine;dihydrochloride Chemical compound Cl.Cl.CCCCN1CCNCC1 SBJSIKFDCGEKRZ-UHFFFAOYSA-N 0.000 description 1
YTPQLWVHCBATKO-UHFFFAOYSA-N 1-propylpiperazine;dihydrobromide Chemical compound Br.Br.CCCN1CCNCC1 YTPQLWVHCBATKO-UHFFFAOYSA-N 0.000 description 1
HQFNAHUCOKGSRS-UHFFFAOYSA-N 2-[4-[3-(6-fluoro-1,2-benzoxazol-3-yl)propyl]piperazin-1-yl]ethanol;dihydrochloride Chemical compound Cl.Cl.C1CN(CCO)CCN1CCCC1=NOC2=CC(F)=CC=C12 HQFNAHUCOKGSRS-UHFFFAOYSA-N 0.000 description 1
125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 1
BXKDFBQWOBXZBD-UHFFFAOYSA-N 3-[3-(4-benzylpiperazin-1-yl)propyl]-6-fluoro-1,2-benzoxazole;dihydrochloride Chemical compound Cl.Cl.N=1OC2=CC(F)=CC=C2C=1CCCN(CC1)CCN1CC1=CC=CC=C1 BXKDFBQWOBXZBD-UHFFFAOYSA-N 0.000 description 1
OFCACCGCSAVUSU-UHFFFAOYSA-N 3-[3-(4-butylpiperazin-1-yl)propyl]-6-fluoro-1,2-benzoxazole;dihydrochloride Chemical compound Cl.Cl.C1CN(CCCC)CCN1CCCC1=NOC2=CC(F)=CC=C12 OFCACCGCSAVUSU-UHFFFAOYSA-N 0.000 description 1
CCBJUDMVMYJZQI-UHFFFAOYSA-N 6-fluoro-3-(3-piperazin-1-ylpropyl)-1,2-benzoxazole Chemical class N=1OC2=CC(F)=CC=C2C=1CCCN1CCNCC1 CCBJUDMVMYJZQI-UHFFFAOYSA-N 0.000 description 1
BRMFYBBVCGKVTI-UHFFFAOYSA-N 6-fluoro-3-[3-(4-phenylpiperazin-1-yl)propyl]-1,2-benzoxazole;oxalic acid Chemical compound OC(=O)C(O)=O.N=1OC2=CC(F)=CC=C2C=1CCCN(CC1)CCN1C1=CC=CC=C1 BRMFYBBVCGKVTI-UHFFFAOYSA-N 0.000 description 1
PHVHMNCNBYPWIW-UHFFFAOYSA-N 6-fluoro-3-[3-[4-(3-methoxyphenyl)piperazin-1-yl]propyl]-1,2-benzoxazole;oxalic acid Chemical compound OC(=O)C(O)=O.COC1=CC=CC(N2CCN(CCCC=3C4=CC=C(F)C=C4ON=3)CC2)=C1 PHVHMNCNBYPWIW-UHFFFAOYSA-N 0.000 description 1
ROAOUFVUUDIBEK-UHFFFAOYSA-N 6-fluoro-3-[3-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]propyl]-1,2-benzoxazole;hydrochloride Chemical compound Cl.N=1OC2=CC(F)=CC=C2C=1CCCN(CC1)CCN1C1=CC=CC(C(F)(F)F)=C1 ROAOUFVUUDIBEK-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
206010052804 Drug tolerance Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
244000246386 Mentha pulegium Species 0.000 description 1
235000016257 Mentha pulegium Nutrition 0.000 description 1
235000004357 Mentha x piperita Nutrition 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
206010061296 Motor dysfunction Diseases 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
208000011644 Neurologic Gait disease Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241000282696 Saimiri sciureus Species 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000002585 base Substances 0.000 description 1
230000006399 behavior Effects 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001055 chewing effect Effects 0.000 description 1
235000015218 chewing gum Nutrition 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
230000001934 delay Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
RWLDAJMGAVDXSH-UHFFFAOYSA-N ethane-1,1,2-tricarboxylic acid Chemical compound OC(=O)CC(C(O)=O)C(O)=O RWLDAJMGAVDXSH-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000010685 fatty oil Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000035929 gnawing Effects 0.000 description 1
230000026781 habituation Effects 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
229960003878 haloperidol Drugs 0.000 description 1
GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
235000001050 hortel pimenta Nutrition 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
229910052808 lithium carbonate Inorganic materials 0.000 description 1
HQRPHMAXFVUBJX-UHFFFAOYSA-M lithium;hydrogen carbonate Chemical compound [Li+].OC([O-])=O HQRPHMAXFVUBJX-UHFFFAOYSA-M 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960001047 methyl salicylate Drugs 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000007968 orange flavor Substances 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
229940124641 pain reliever Drugs 0.000 description 1
YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
150000003053 piperidines Chemical class 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
235000015497 potassium bicarbonate Nutrition 0.000 description 1
239000011736 potassium bicarbonate Substances 0.000 description 1
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
GZRKXKUVVPSREJ-UHFFFAOYSA-N pyridinylpiperazine Chemical compound C1CNCCN1C1=CC=CC=N1 GZRKXKUVVPSREJ-UHFFFAOYSA-N 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000004208 shellac Substances 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000010454 slate Substances 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000004289 sodium hydrogen sulphite Substances 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
235000009518 sodium iodide Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000011699 spontaneously hypertensive rat Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000010959 steel Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
238000012549 training Methods 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)

NO823556A 1982-04-09 1982-10-26 1-(3-(6-fluor-1,2-benzisoksazol-3-yl)propyl)-4-(substituert)-piperaziner og -piperidiner, fremgangsmaate til fremstilling av disse, farmasoeytiske blandinger inneholdende disse og deres bruk som legemidler NO823556L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US06/366,244 US4390544A (en)	1982-04-09	1982-04-09	{1-[3-(6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-4-(2-oxo-1-benzimidazolinyl}p
US06/366,248 US4536578A (en)	1982-04-09	1982-04-09	1-[3-(6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-4-(substituted)piperazines

Publications (1)

Publication Number	Publication Date
NO823556L true NO823556L (no)	1983-10-10

Family

ID=27003274

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO823556A NO823556L (no)	1982-04-09	1982-10-26	1-(3-(6-fluor-1,2-benzisoksazol-3-yl)propyl)-4-(substituert)-piperaziner og -piperidiner, fremgangsmaate til fremstilling av disse, farmasoeytiske blandinger inneholdende disse og deres bruk som legemidler

Country Status (16)

Country	Link
EP (1)	EP0091511B1 (el)
KR (1)	KR880002013B1 (el)
AT (1)	ATE34170T1 (el)
CA (1)	CA1209146A (el)
DE (1)	DE3278471D1 (el)
DK (1)	DK474382A (el)
ES (1)	ES516830A0 (el)
FI (1)	FI823433L (el)
GR (1)	GR77706B (el)
HU (1)	HU191075B (el)
IE (1)	IE54065B1 (el)
IL (1)	IL66866A (el)
NO (1)	NO823556L (el)
NZ (1)	NZ202044A (el)
PH (1)	PH18252A (el)
PT (1)	PT75726A (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2807577B2 (ja) *	1990-06-15	1998-10-08	エーザイ株式会社	環状アミド誘導体
US5055476A (en) *	1990-08-13	1991-10-08	Hoechst-Roussel Pharmaceuticals Incorporated	3-(1,2-benzisoxazol-3-yl)-4-pyridinamines and derivatives
US5114936A (en) *	1990-08-23	1992-05-19	Hoechst-Roussel Pharmaceuticals Incorporated	6,7-dihydro-3-phenyl-1,2-benzisoxazol-4(5h)-ones and -ols, compositions and pharmaceutical use
US5750542A (en)	1993-09-28	1998-05-12	Pfizer	Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
ATE231505T1 (de) *	1991-03-28	2003-02-15	Eisai Co Ltd	Neue heterocyclische/cyclische amine
US5143923B1 (en) *	1991-04-29	1993-11-02	Hoechst-Roussel Pharmaceuticals Incorporated	Benzoisothiazole-and benzisoxazole-3-carboxamides
US5225412A (en) *	1991-04-29	1993-07-06	Hoechst-Roussel Pharmaceuticals Incorporated	Benzoisothiazole-and benzisoxazole-3-carboxamides
BR112015013971B1 (pt) *	2012-12-19	2021-11-23	Henkel Ag & Co. Kgaa	Método para amortecimento de som e/ou isolamento de som de componentes metálicos e/ou componentes plásticos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI60390C (fi) *	1975-03-05	1982-01-11	Sumitomo Chemical Co	Foerfarande foer framstaellning av neuroleptiska butyrofenoner
JPS51136666A (en) *	1975-05-19	1976-11-26	Dainippon Pharmaceut Co Ltd	Process for preparing 3-aminoalkyl-1,2-benzisoxazole derivatives.
JPS6043064B2 (ja) *	1979-11-28	1985-09-26	ウェルファイド株式会社	新規イソオキサゾ−ル誘導体

1982
- 1982-09-24 IL IL66866A patent/IL66866A/xx unknown
- 1982-09-30 NZ NZ202044A patent/NZ202044A/en unknown
- 1982-10-08 FI FI823433A patent/FI823433L/fi not_active Application Discontinuation
- 1982-10-22 PT PT75726A patent/PT75726A/pt unknown
- 1982-10-22 GR GR69603A patent/GR77706B/el unknown
- 1982-10-23 AT AT82109801T patent/ATE34170T1/de not_active IP Right Cessation
- 1982-10-23 DE DE8282109801T patent/DE3278471D1/de not_active Expired
- 1982-10-23 EP EP82109801A patent/EP0091511B1/en not_active Expired
- 1982-10-26 ES ES516830A patent/ES516830A0/es active Granted
- 1982-10-26 DK DK474382A patent/DK474382A/da not_active Application Discontinuation
- 1982-10-26 IE IE2558/82A patent/IE54065B1/en unknown
- 1982-10-26 PH PH28037A patent/PH18252A/en unknown
- 1982-10-26 CA CA000414215A patent/CA1209146A/en not_active Expired
- 1982-10-26 NO NO823556A patent/NO823556L/no unknown
- 1982-10-26 KR KR8204814A patent/KR880002013B1/ko active
- 1982-10-26 HU HU823415A patent/HU191075B/hu not_active IP Right Cessation

Also Published As

Publication number	Publication date
IL66866A0 (en)	1982-12-31
DK474382A (da)	1983-10-10
NZ202044A (en)	1987-04-30
DE3278471D1 (en)	1988-06-16
ES8400431A1 (es)	1983-10-16
IE54065B1 (en)	1989-06-07
KR880002013B1 (ko)	1988-10-12
GR77706B (el)	1984-09-25
EP0091511A2 (en)	1983-10-19
ATE34170T1 (de)	1988-05-15
PT75726A (en)	1982-11-01
PH18252A (en)	1985-05-13
CA1209146A (en)	1986-08-05
KR840001974A (ko)	1984-06-07
FI823433A0 (fi)	1982-10-08
EP0091511A3 (en)	1984-12-12
EP0091511B1 (en)	1988-05-11
ES516830A0 (es)	1983-10-16
HU191075B (en)	1987-01-28
FI823433L (fi)	1983-10-10
IE822558L (en)	1983-10-09
IL66866A (en)	1987-08-31

Publication	Publication Date	Title
RU2039057C1 (ru)	1995-07-09	Бензизотиазол- или бензизоксазол-3-карбоксамиды или их фармацевтически приемлемые соли, способы их получения и фармацевтическая композиция, обладающая антипсихотической активностью
EP0079564B1 (en)	1986-03-19	3-(1-substituted-4-piperidyl)-1,2-benzisoxazoles, a process for the preparation thereof, a pharmaceutical composition comprising the same, and their use as medicaments
NO158419B (no)	1988-05-30	Analogifremgangsmaate til fremstilling av terapeutisk aktive 1,2-diaminocyklobuten-3,4-dioner.
NO176143B (no)	1994-10-31	Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-[4(1-substituert 4-piperazinyl)butylÅ-4-tiazlidinoner
NO823556L (no)	1983-10-10	1-(3-(6-fluor-1,2-benzisoksazol-3-yl)propyl)-4-(substituert)-piperaziner og -piperidiner, fremgangsmaate til fremstilling av disse, farmasoeytiske blandinger inneholdende disse og deres bruk som legemidler
NO170582B (no)	1992-07-27	Analogifremgangsmaate for fremstilling av terapeutisk aktive aryl-piperazinyl-alkylenfenyl-heterocykliske forbindelser
EP0091512B1 (en)	1988-05-11	6-fluoro-3-(3-(1-heterocyclo)propyl)-1,2-benzisoxazoles, a process for their preparation, pharmaceutical compositions thereof and their use as medicaments
RU2038355C1 (ru)	1995-06-27	Способ получения 3-(1-тиазолидинилбутил-4-пиперазинил)-1н-индазолов
US4536578A (en)	1985-08-20	1-[3-(6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-4-(substituted)piperazines
HU195200B (en)	1988-04-28	Process for producing oxo-thiazolidine compounds and pharmaceutical preparations comprising the same
US4396770A (en)	1983-08-02	1-[3-(6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-4-hydroxy-4-phenylpiperidines
US4604395A (en)	1986-08-05	1-[3-(6-fluoro-1,2-benzisoxazol-3-yl)propyl]-4-(substituted)piperazines
US4610988A (en)	1986-09-09	1-[3-(6-fluoro-1,2-benzisoxazol-3-yl)propyl]-4-(substituted)piperazines useful for alleviating pain
US4390544A (en)	1983-06-28	{1-[3-(6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-4-(2-oxo-1-benzimidazolinyl}p
US4609658A (en)	1986-09-02	1-[3-(6-fluoro-1,2-benzisoxazol-3-yl)propyl]-4-(substituted) piperazines useful for reducing blood pressure
NO126693B (el)	1973-03-12
NO821361L (no)	1982-10-28	Nye 1-(3-(6-fluor-1,2-benzisoksazol-3-yl)propyl)-4-hydroksy-4-fenylpiperidiner, fremgangsmaate og mellomprodukter for deres fremstilling og deres bruk som legemidler
US4598152A (en)	1986-07-01	6-fluoro-3-[3-(oxoheterocyclo)propyl]-1,2-benzisoxazoles
KR880002511B1 (ko)	1988-11-26	1-[3-(6-플루오로-1,2-벤즈이속사졸-3-일)프로필]-4-(치환된)-피페리딘 및 이의 제조방법
US4415581A (en)	1983-11-15	1-[3-6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-4-hydroxy-4-phenylpiperidines to treat psychoses
US4591586A (en)	1986-05-27	6-fluoro-3-[3-(1-heterocyclo)propyl]-1,2-benzisoxazoles for treatment of pain, hypertension and psychoses
US4826846A (en)	1989-05-02	Arylpiperazinylalkoxy derivatives of cyclic imides to treat anxiety
US4416887A (en)	1983-11-22	1-[3-(6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-4-hydroxyl-4-phenylpiperidines to treat pain
CS252828B2 (en)	1987-10-15	Method of n,3-disubstituted 2-oxindole-1-carboxamides production
PT87461B (pt)	1992-09-30	Processo para a preparacao de 1-{n-(2-alquiltio-10h-fenotiazin-10-il)alquil}-4-benzoilpiperidinas e de composicoes farmaceuticas que os contem